AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data

Core Insights - AtaiBeckley Inc. has reported positive topline results from a Phase 2a trial of EMP-01, an oral R-MDMA treatment for Social Anxiety Disorder, indicating a favorable safety profile and significant patient improvement [1][4] Social Anxiety Data - In the trial, 49% of patients receiving EMP-01 were rated as "very much improved" or "much improved," compared to only 15% in the placebo group, resulting in a 34-percentage-point difference and a Number Needed to Treat (NNT) of 2.95, indicating clinically meaningful improvement [2] - EMP-01 showed improvements in both Fear and Avoidance sub-domains of the Liebowitz Social Anxiety Scale (LSAS), with notable reductions in social avoidance behaviors after two administrations over six weeks, without the need for adjunctive psychotherapy [3] Technical Analysis - The stock is currently trading 10.5% below its 20-day simple moving average (SMA) and 5.2% below its 100-day SMA, indicating short-term weakness, despite a 43% increase in shares over the past 12 months [5] - The Relative Strength Index (RSI) is at 50.00, suggesting neutral territory, while the MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock [6] Price Action - AtaiBeckley shares were down 10.60% at $3.88 at the time of publication, with key resistance identified at $5.00 and key support at $4.00 [7]